Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Genprex, Inc. (GNPX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.53, with a market capitalisation of $2.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.30 to $1,210.00. This page covers its latest market performance, valuation, price trends and company information.
$2.83M | |
$3.53 | |
$855,795.60 | |
$3.30 | |
$3.31 | |
-- | |
174.20K | |
-- | |
$1,210.00 | |
$3.30 | |
-- | |
-- |
Genprex, Inc. (GNPX) is trading at $3.53 in pre-market trading as of 2026-09-16 08:01:00, up 6.62% ($0.22) from the previous close of $3.31
Pre-market trading shows how investors are pricing GNPX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Genprex, Inc. (GNPX) moved from $3.50 to $3.53, representing a gain of 0.83% ($0.03).
The stock traded between $3.30 and $3.65 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 31.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
GNPX is currently trading at $3.53, placing it 0.0% of the way from its 52-week low of $3.30 to its 52-week high of $1,210.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genprex, Inc. (GNPX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.